572 related articles for article (PubMed ID: 28362135)
21. Immunogenicity evaluation of primary polio vaccination schedule with inactivated poliovirus vaccines and bivalent oral poliovirus vaccine.
Xu J; Liu Y; Qiu W; Li W; Hu X; Li X; Fan Q; Tang W; Wang Y; Wang Q; Yao N
BMC Infect Dis; 2024 May; 24(1):535. PubMed ID: 38807038
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of poliovirus vaccines in chronically malnourished infants: a randomized controlled trial in Pakistan.
Saleem AF; Mach O; Quadri F; Khan A; Bhatti Z; Rehman NU; Zaidi S; Weldon WC; Oberste SM; Salama M; Sutter RW; Zaidi AK
Vaccine; 2015 Jun; 33(24):2757-63. PubMed ID: 25917673
[TBL] [Abstract][Full Text] [Related]
23. [Observation on safety of sequential vaccination schedule of different strain inactivated poliovirus vaccines].
Huang ZY; Sun XD; Liu JC; Li Z; Ren J; Wu LL; Hu JY; Zhang JN
Zhonghua Liu Xing Bing Xue Za Zhi; 2019 May; 40(5):565-570. PubMed ID: 31177739
[No Abstract] [Full Text] [Related]
24. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.
Sáez-Llorens X; Clemens R; Leroux-Roels G; Jimeno J; Clemens SA; Weldon WC; Oberste MS; Molina N; Bandyopadhyay AS
Lancet Infect Dis; 2016 Mar; 16(3):321-30. PubMed ID: 26719058
[TBL] [Abstract][Full Text] [Related]
26. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
27. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
29. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
30. The effect of diarrheal disease on bivalent oral polio vaccine (bOPV) immune response in infants in Nepal.
Cardemil CV; Estivariz C; Shrestha L; Sherchand JB; Sharma A; Gary HE; Oberste MS; Weldon WC; Bowen MD; Vinjé J; Schluter WW; Anand A; Mach O; Chu SY
Vaccine; 2016 May; 34(22):2519-26. PubMed ID: 27085172
[TBL] [Abstract][Full Text] [Related]
31. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
[TBL] [Abstract][Full Text] [Related]
32. [Surveillance of immunization effectiveness and titer of type Ⅰ and type Ⅲ polio vaccine in Beijing before and after the adjustment of immunization strategy in 2012-2018].
Li J; Zhang ZJZ; Pan JB; Zhang HR; Li RQ; Li MZ; Lu L; Huang F; Wu J
Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Jul; 54(7):779-783. PubMed ID: 32842302
[No Abstract] [Full Text] [Related]
33. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
34. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis.
Jaiswal N; Singh S; Agarwal A; Chauhan A; Thumburu KK; Kaur H; Singh M
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011780. PubMed ID: 31858595
[TBL] [Abstract][Full Text] [Related]
35. Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
Resik S; Tejeda A; Mach O; Fonseca M; Diaz M; Alemany N; Heng Hung L; Aleman Y; Mesa I; Garcia G; Sutter RW
Clin Infect Dis; 2018 Oct; 67(suppl_1):S51-S56. PubMed ID: 30376088
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants.
Fadlyana E; Dhamayanti M; Tarigan R; Mulia Sari R; Sjafri Bachtiar N; Kartasasmita CB; Rusmil K
Vaccine; 2020 Feb; 38(8):1962-1967. PubMed ID: 31982261
[TBL] [Abstract][Full Text] [Related]
37. Impact of Maternal Antibody on the Immunogenicity of Inactivated Polio Vaccine in Infants Immunized With Bivalent Oral Polio Vaccine: Implications for the Polio Eradication Endgame.
Gaensbauer JT; Gast C; Bandyopadhyay AS; O'Ryan M; Saez-Llorens X; Rivera L; Lopez-Medina E; Melgar M; Weldon WC; Oberste MS; Rüttimann R; Clemens R; Asturias EJ
Clin Infect Dis; 2018 Oct; 67(suppl_1):S57-S65. PubMed ID: 30376095
[TBL] [Abstract][Full Text] [Related]
38. Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis.
Macklin GR; Grassly NC; Sutter RW; Mach O; Bandyopadhyay AS; Edmunds WJ; O'Reilly KM
Lancet Infect Dis; 2019 Oct; 19(10):1121-1128. PubMed ID: 31350192
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
[TBL] [Abstract][Full Text] [Related]
40. Monovalent type-1 oral poliovirus vaccine given at short intervals in Pakistan: a randomised controlled, four-arm, open-label, non-inferiority trial.
Mir F; Quadri F; Mach O; Ahmed I; Bhatti Z; Khan A; Rehman NU; Durry E; Salama M; Oberste SM; Weldon WC; Sutter RW; Zaidi AK
Lancet Infect Dis; 2015 Aug; 15(8):889-97. PubMed ID: 26093979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
